UniQure Climbs on Scheduling FDA Meeting for Huntington's Disease Treatment
By Elias Schisgall
Shares of UniQure were higher after the gene therapy company said it had scheduled a Type A meeting with the Food and Drug Administration to discuss a Biologics License Application for the company's investigational Huntington's disease treatment.
The stock was up 17% at $26.99 Friday morning. The stock has nearly doubled in value in the past year.
The company said Friday that the meeting would discuss accelerated approval of the treatment, known as AMT-130.
"We look forward to a constructive discussion with the FDA as we work toward a timely resolution regarding an accelerated approval pathway for AMT-130," Chief Executive Officer Matt Kapusta said.
"The Huntington's disease community, including patients and clinicians, has emphasized the profound unmet medical need and the importance of timely access to potentially disease-modifying therapies such as AMT-130," Kapusta added. We remain deeply committed to patient access while continuing to collaborate closely with the FDA."
Write to Elias Schisgall at elias.schisgall@wsj.com
(END) Dow Jones Newswires
January 09, 2026 10:14 ET (15:14 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
5 Stocks to Sell for Tax-Loss Harvesting
33 Undervalued Stocks to Buy Before the Market Shifts Again
What’s Ahead for Stocks This Quarter—and Where to Invest
Ask the Analyst: What Is the Best Source for Low-Risk Tax-Free Income?
United States